[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-neoplasm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053600","phase-1-a-clinical-study-of-mk-8294-in-participants-with-advanced-solid-tumors-mk-8294-001-100053600",false,"NCT07030712","A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)","A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-8294 Monotherapy in Advanced Solid Tumors","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically or cytologically confirmed advanced\u002Fmetastatic solid tumor; including head and neck squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, breast cancer (triple negative breast cancer, Estrogen Receptor \\[ER\\]\u002Fprogesterone receptor +, human epidermal growth factor receptor 2 negative \\[HER2-\\]), endometrial, and bladder cancer by pathology report and have previously failed standard treatment, lack standard treatment options, or are intolerant to standard treatment\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has a history of New York Heart Association Class II or greater heart failure\n* Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis\n* Has ongoing radiation-related toxicities, requiring corticosteroids\n* Has known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid)\n* Has active infection requiring systemic therapy\n* Has history of stem cell\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery or have ongoing surgical complications","ALL","18 Years",{"count":19,"type":20},67,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.",[26],"Metastatic Neoplasm",[28,29],"Metastases","Neoplasm","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2025-07-23",{"date":38,"type":20},"2027-08-23",{"name":40,"class":41},"Merck Sharp & Dohme LLC","INDUSTRY",6,{"id":44,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":46,"briefSummary":24,"conditions":47,"keywords":48,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":53,"leadSponsor":54,"locationsCount":55},"100595304",{"count":19,"type":20},[23],[26],[28,29],"2026-03-12",{"date":51,"type":34},"2026-03-16",{"date":36,"type":34},{"date":38,"type":20},{"name":40,"class":41},5,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100486718","phase-2-spine-radiosurgery-for-symptomatic-metastatic-neoplasms-100486718","NCT05617716","Spine Radiosurgery for Symptomatic Metastatic Neoplasms","Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN) Multicenter Randomized Phase II Clinical Trial","SPORTSMEN","Inclusion Criteria:\n\n* Participant must have histologic confirmation of malignancy. Spinal metastatic disease must be confirmed by imaging.\n* Participant must have received no prior therapies for this disease. Prior therapy includes previous radiation therapy encompassing the anatomic site to be treated with spine SBRT. This includes any previous radiation therapy where the treatment field overlaps with the anatomic site to be treated with spine SBRT (even if that previous radiation therapy was not for treatment of spinal disease). Systemic radiation therapy for metastatic disease such as Pluvicto also counts as previous radiation therapy.\n* Age \\>18 years. This study requires informed consent by the participant; as children are not able to perform this without parental approval, Participant \\\u003C age 18 are excluded from this study.\n* Life expectancy of≥ 3 months, in the opinion of and as documented by the investigator.\n* Participant must have a worst pain score \\\u003C 2 of 10 according to the Brief Pain Inventory\n* Participant must have no intention of changing pain medications on the first day of SBRT\n* Participant must have a Spinal Instability score (SINS) ≤ 12\n* Participant must be a spine SBRT candidate per Radiation Oncology\n* Participant must have the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Participant receiving any other investigational agents.\n* Participant with prognosis less than 3 months will be excluded from this clinical trial because of their poor prognosis and decreased likelihood to meet the primary endpoint\n* Participant with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant or nursing Participant are excluded due to toxicity of radiation therapy.\n* Participant is unable to receive MRI of the spine\n* Participant has a Spinal Instability in Neoplasia score (SINS) ≥ 12\n* Participant has received previous stereotactic radiosurgery where the 50% isodose line overlaps with current treatment field\n* Participant has more than 3 consecutive vertebral bodies in the SBRT treatment volume\n* Participant is not an SBRT candidate per radiation oncology discretion\n* Participant has a known primary and has an estimated median survival≤ 3 months\n* Participant has an unknown primary\n* Participant has a Brief Pain Inventory score \\> 2\n* Participant has received previous radiation therapy involving the intended SBRT treatment field\n* Participant has received previous spinal surgical procedure involving the SBRT target volume. Biopsy is not considered a previous spinal surgical procedure.\n* Participant has neurological deficits from malignant cauda equina compression or epidural spinal cord compression",{"count":65,"type":20},240,[67],"PHASE2","The purpose of this study is to compare three types of radiation therapy for cancer that has spread to the spine. The two types of radiation therapy used in this trial are External Beam Radiation Therapy (EBRT) and Stereotactic Body Radiation Therapy (SBRT). EBRT delivers tightly targeted radiation beams from outside the body. SBRT is a specialized type of radiation therapy that allows high doses of radiation to small targets. This study will include standard dose SBRT and higher dose SBRT. Each participant will be randomly assigned to either EBRT, standard dose SBRT, or higher dose SBRT.",[70,26],"Metastatic Neoplasm to the Spine",[72,73,74,75],"Radiosurgery","External Beam Radiation Therapy","Stereotactic Body Radiation Therapy","Spine Stereotactic Radiosurgery","2025-10-15",{"date":78,"type":34},"2025-10-20",{"date":80,"type":34},"2025-09-09",{"date":82,"type":20},"2029-09-30",{"name":84,"class":85},"University of Oklahoma","OTHER",2]